Skip to main content

Table 6 Relative expression of mRNA levels in tumor samples after ex vivo exposure to topotecan and irinotecan. The IC50 concentrations for the samples tested are shown for each drug (median and range). The p values have been calculated using non-parametric statistics, in detail the Wilcoxon matched pairs test. On statistical advice, we chose not to use a Bonferroni's correction, but it should be noted that some technically statistically significant results could have arisen by chance.

From: Cancer cell adaptation to chemotherapy

  Ovarian samples Colorectal samples
Target gene n Control Topotecan IC50 = 0.754 μM (0.164–4.82) p n Control Irinotecan IC50 = 55.4 μM (29.5–100) p
BCRP 9 0.0156 0.0125 >0.999 7 0.0354 0.0515 0.6875
COX-2 10 0.253 0.475 0.7695 7 105.17 38.49 0.0156
EGFR 10 0.470 0.163 0.0039 - - - -
ERCC1 10 0.252 0.399 0.002 7 1.403 2.469 0.0156
MDR1 9 0.0090 0.0034 0.5703 7 0.2253 0.2938 >0.999
MLH1 10 0.263 0.2268 0.0371 - - - -
MRP1 - - - - 7 5.132 3.775 0.0156
TOPO I 10 4.490 2.448 0.0371 7 1.468 1.119 0.1094
TOPO IIα 10 1.093 0.0670 0.002 6 0.2847 0.0733 0.2188
TOPO IIβ - - - - 7 0.7405 0.5058 0.0313